cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Regenxbio Inc
2 own
3 watching
Current Price
$23.13
$0.13
(0.57%)
logo-rgnx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,001.34M
52-Week High
52-Week High
35.73
52-Week Low
52-Week Low
18.69
Average Volume
Average Volume
0.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
44.65
iconMarket Capitalization1,001.34M
icon52-Week High35.73
icon52-Week Low18.69
iconAverage Volume0.3M
iconDividend Yield--
iconP/E Ratio44.65
What does the Regenxbio Inc do?
Developing gene therapies for rare diseases with a proprietary delivery platform.
Read More
How much money does Regenxbio Inc make?
News & Events about Regenxbio Inc.
Globe Newswire
3days ago
- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy intended for treatment of patients with Duchenne muscular dystrophy - - White paper submitted to the U.S...
PR Newswire
6days ago
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients PR...
PR Newswire
26days ago
REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire ROCKVILLE, Md., Jan. 3, 2023 ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX) today...
PR Newswire
1month ago
REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease PR Newswire ROCKVILLE, Md., Dec. 21, 2022 RGX-181 and RGX-381 are potential one-time AAV Therapeutics for the treatment of the CNS and ocular manifestations of...
PR Newswire
1month ago
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I PR Newswire ROCKVILLE, Md., Dec. 8, 2022 RGX-111 is an investigational AAV...
Frequently Asked Questions
Frequently Asked Questions
What is Regenxbio Inc share price today?
plus_minus_icon
Can Indians buy Regenxbio Inc shares?
plus_minus_icon
How can I buy Regenxbio Inc shares from India?
plus_minus_icon
Can Fractional shares of Regenxbio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Regenxbio Inc stocks?
plus_minus_icon
What is today’s traded volume of Regenxbio Inc?
plus_minus_icon
What is today’s market capitalisation of Regenxbio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Regenxbio Inc?
plus_minus_icon
What percentage is Regenxbio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Regenxbio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$23.13
$0.13
(0.57%)
logo-rgnx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$13.64
$-0.37 (-2.64 %)
Vericel Corporation
Vericel Corporation
$28.53
$0.68 (2.44 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$10.56
$0.04 (0.38 %)
AxoGen, Inc.
AxoGen, Inc.
$10.21
$0.23 (2.30 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$13.64
$-0.37 (-2.64 %)
Vericel Corporation
Vericel Corporation
$28.53
$0.68 (2.44 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$10.56
$0.04 (0.38 %)
AxoGen, Inc.
AxoGen, Inc.
$10.21
$0.23 (2.30 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00